Biodefense

Biodefense

Global travel and economic interconnectedness make infectious disease prevention and preparedness high priorities for populations and governments throughout the world. The recent outbreaks of Zika virus and Ebola illustrate that emerging viruses can create a public health crisis. Kineta’s antiviral pipeline addresses the growing needs for biodefense preparedness.

Kineta is advancing two types of broad spectrum antiviral drugs: LHF-535 for arenaviruses including Lassa fever and innate immune antivirals that can target multiple virus families. Additionally, we are developing immune modulating vaccine adjuvants for highly pathogenic influenza can enhance the efficacy of existing vaccines through a balanced immune response while using lower vaccine doses.

Kineta is working in collaboration with the National Institutes of Health (NIH), the Wellcome Trust and other organizations to advance our research that can address future emerging viral disease outbreaks. Our novel medical countermeasures that are in development hold the promise to halt the spread of disease and allow communities to return to normalcy more rapidly.